ArticleGland surgery2026
Optimal extent of thyroidectomy in clinically node-negative unilateral papillary thyroid carcinoma >1 cm and ≤4 cm.
Article in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal extent of thyroidectomy for papillary thyroid carcinoma (PTC) measuring >1 cm and ≤4 cm remains a subject of debate. This study aimed to determine the optimal surgical extent for clinically node-negative (cN0) unilateral PTC measuring >1 cm and ≤4 cm and to identify factors associated with recurrence risk. Methods: We conducted a retrospective analysis of 403 patients with unilateral cN0 PTC measuring 11-40 mm. Propensity score-matched (PSM) analysis was performed using five covariates including age, sex, tumor size, central neck dissection, and follow-up duration. Patients were stratified by tumor size (11-20 Results: In the baseline cohorts, among the 403 patients, 304 had 11-20 mm tumors, and 99 had 21-40 mm PTC. Total thyroidectomy was performed in 65.3% of cases. Rates of minimal ETE and strap muscle invasion were 41.4% and 8.2%, respectively. Recurrence rates did not differ significantly by tumor size, ETE status (except strap muscle invasion), or surgical extent. Strap muscle invasion independently predicted recurrence [hazard ratio (HR) =6.380, P=0.01] and was associated with poorer disease-free survival. After PSM, 88 pairs of patients were generated in the lobectomy and total thyroidectomy groups. In the PSM cohort, the recurrence rate did not differ between the two groups. However, the overall complication rate was significantly higher in the total thyroidectomy group (49.5% Conclusions: In patients with unilateral cN0 PTC measuring 11-40 mm, lobectomy may serve as an appropriate primary surgical option, providing disease control comparable to total thyroidectomy while reducing procedure-related complications, except in those with strap muscle invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.